Ivabradine Anpharm

Ivabradine, the active ingredient in Ivabradine Anpharm, is an If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina pectoris and for heart failure with reduced ejection fraction in appropriate adult patients.

GNH USA supplies Ivabradine Anpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from regulatory support, batch traceability, and responsive technical assistance throughout the supply chain.

Ivabradine acts on the cardiac If current to lower heart rate in conditions where rate control improves outcomes. - Chronic stable angina pectoris: improves exercise tolerance by reducing heart rate. - Heart failure with reduced ejection fraction (HFrEF): lowers hospitalization risk by decreasing heart rate. - Patients with elevated resting heart rate where beta‑blockers are insufficient: provides heart‑rate reduction without affecting contractility.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Bradycardia: symptomatic slowing of heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness: especially on standing. - Fatigue: generalised tiredness. - Hypertension: occasional rise in blood pressure.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation: new‑onset irregular rhythm. - Symptomatic hypotension: marked drop in blood pressure. - Persistent visual impairment: prolonged phosphene episodes. - Allergic reactions: rash, pruritus, or angioedema. - Cardiac arrest: extremely rare but life‑threatening.

Before initiating ivabradine, clinicians should assess patient suitability and monitor for specific risks. - Cardiac monitoring: obtain baseline heart rate and ECG, and re‑evaluate periodically. - Hepatic impairment: avoid or adjust dose in severe liver disease. - Sick sinus syndrome: contraindicated in patients with intrinsic sinus node dysfunction. - CYP3A4 inhibitors: avoid concomitant use with strong inhibitors such as ketoconazole or clarithromycin. - Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradine may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly increase ivabradine plasma levels. - Concomitant use with other If channel inhibitors: additive heart‑rate reduction. - Certain anti‑arrhythmic agents (e.g., amiodarone): may exacerbate bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): require dose adjustment and close monitoring. - Beta‑blockers or digoxin: combined effect on heart rate may necessitate titration. - Diuretics causing electrolyte shifts: monitor for arrhythmias.